Johnson & Johnson.
- JNJ · NYSE
- Pharmaceutical Preparations
- New Brunswick, NJ
- 138,200 employees
- CIK 0000200406
Updated from SEC filings through
Top things to know
Executives
- Joaquin Duato CEO and Chairman of the Board 4, 2026-08-14
-
Joseph J. Wolk Exec VP, CFO 4, 2026-02-18 - Elizabeth Forminard EVP, Chief Legal Officer 4, 2026-08-07
- Kathryn E. Wengel EVP, Chief TO and Risk Officer 4, 2026-06-12
- Kristen Mulholland EVP, Chief HR Officer 4, 2026-02-18
- R. J. Decker Jr. Controller and Chief Accounting Officer (Principal Accounting Officer) 10-K, 2026-02-11
What leadership is saying
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio”
Earnings press release (8-K Ex. 99.1), filed October 13, 2026
Johnson & Johnson is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in New Brunswick, NJ. It trades as JNJ on NYSE. Revenue was $94.2B in the fiscal year ending December 28, 2025, +6.0% from the year before. It reported about 138,200 employees. Joaquin Duato is CEO and Chairman of the Board.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $94.2B 10-K, 2026-02-11 | $88.8B 10-K, 2026-02-11 | $85.2B 10-K, 2026-02-11 | $80.0B 10-K, 2025-02-13 | $78.7B 10-K, 2024-02-16 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $23.7B 10-K, 2026-02-11 | $22.9B 10-K, 2026-02-11 | $21.5B 10-K, 2026-02-11 | $20.2B 10-K, 2025-02-13 | $20.1B 10-K, 2024-02-16 |
| Net income | $26.8B 10-K, 2026-02-11 | $14.1B 10-K, 2026-02-11 | $35.2B 10-K, 2026-02-11 | $17.9B 10-K, 2025-02-13 | $20.9B 10-K, 2024-02-16 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Joaquin Duato Tackling the world’s toughest health challenges as Chairman and Chief Executive Officer of Johnson & Johnson | CEO and Chairman of the Board | 4, 2026-08-14 |
| Joseph J. Wolk | Exec VP, CFO | 4, 2026-02-18 |
| Elizabeth Forminard Executive Vice President, Chief Legal Officer | EVP, Chief Legal Officer | 4, 2026-08-07 |
| Kathryn E. Wengel EVP, Chief Technical Operations & Risk Officer for Johnson & Johnson | EVP, Chief TO and Risk Officer | 4, 2026-06-12 |
| Kristen Mulholland | EVP, Chief HR Officer | 4, 2026-02-18 |
| R. J. Decker Jr. | Controller and Chief Accounting Officer (Principal Accounting Officer) | 10-K, 2026-02-11 |
| Timothy Schmid | EVP, WW Chair, MedTech | 4, 2026-09-04 |
| Thomas Cavanaugh | EVP WW Chair, Innovative Med. | 3, 2026-09-01 |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | 4, 2026-08-18 |
| Vanessa Broadhurst EVP, Global Corporate Affairs, Johnson & Johnson | Corporate Board Director | EVP, Global Corp Affairs | 4, 2026-07-21 |
| John C. Reed | EVP, Innovative Medicine, R&D | 4, 2026-05-04 |
| Jennifer A. Doudna | Board member (per proxy) bio: Ph.D. | DEF 14A, 2026-03-11 |
| Robert J. Decker | VP Corporate Controller | 4, 2026-03-03 |
| James D. Swanson | EVP, CIO | 4, 2026-02-18 |
| Marillyn Hewson | Board member (per proxy) bio: Director | DEF 14A, 2026-03-11 |
What Johnson & Johnson does
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
Item 1. Business, 10-K for the year ending December 28, 2025
Shares and governance
| Shares outstanding | 2.41 billion (as of October 15, 2026) | 10-Q, October 21, 2026 |
|---|---|---|
| Public float | $367B (as of June 29, 2025) | 10-K, February 11, 2026 |
| Reportable segments | 2 (period ending September 27, 2026) | 10-Q, October 21, 2026 |
| Latest proxy statement | Meeting March 11, 2026 (filed March 11, 2026) | DEF 14A, March 11, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 2, 2026 | Timothy Schmid EVP, WW Chair, MedTech | Sale | 33,597 | $9.2M | Form 4, September 4, 2026 |
| August 17, 2026 | Jennifer L. Taubert EVP, WWC. Innovative Medicine | Sale | 15,000 | $4.0M | Form 4, August 18, 2026 |
| August 13, 2026 | Joaquin Duato CEO and Chairman of the Board | Sale | 123,291 | $32.2M | Form 4, August 14, 2026 |
| August 6, 2026 | Elizabeth Forminard EVP, Chief Legal Officer | Sale | 15,918 | $4.1M | Form 4, August 7, 2026 |
| August 5, 2026 | Joaquin Duato CEO and Chairman of the Board | Sale | 48,480 | $12.5M | Form 4, August 7, 2026 |
| July 20, 2026 | Vanessa Broadhurst EVP, Global Corp Affairs | Sale | 23,054 | $5.8M | Form 4, July 21, 2026 |
| June 11, 2026 | Kathryn E. Wengel EVP, Chief TO and Risk Officer | Sale | 10,000 | $2.4M | Form 4, June 12, 2026 |
| February 27, 2026 | Robert J. Decker VP Corporate Controller | Sale | 4,075 | $1.0M | Form 4, March 3, 2026 |
Recent 8-K events
- 8-K filed 2026-10-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-04
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-07-29
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-28
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-15
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-28
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-14
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
- 8-K filed 2026-01-21
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-14
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
- 8-K filed 2025-09-09
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Johnson & Johnson
- What does Johnson & Johnson do?
- In its own words, from Item 1 of its 10-K: "Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887."
- What is Johnson & Johnson's revenue?
- $94.2B for the fiscal year ending December 28, 2025, from its 10-K filed February 11, 2026.
- Is Johnson & Johnson profitable?
- Johnson & Johnson reported net income of $26.8B for the fiscal year ending December 28, 2025.
- How many employees does Johnson & Johnson have?
- About 138,200 as of February 11, 2026, as stated in its annual report.
- Who is the CEO of Johnson & Johnson?
- Joaquin Duato, CEO and Chairman of the Board, as named in a 4 filed August 14, 2026.
- Who is the CFO of Johnson & Johnson?
- Joseph J. Wolk, Exec VP, CFO, as named in a 4 filed February 18, 2026.
- Where is Johnson & Johnson headquartered?
- New Brunswick, NJ.
- What is Johnson & Johnson's stock ticker?
- JNJ on NYSE.
- What industry is Johnson & Johnson in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Johnson & Johnson's website?
- jnj.com. Investor relations: https://www.investor.jnj.com/overview/default.aspx.
- When does Johnson & Johnson report earnings next?
- January 13, 2027. Source: estimate_8k_pattern.
- Is Johnson & Johnson a public company?
- Yes. Johnson & Johnson files with the SEC under CIK 0000200406 and trades as JNJ.
- Who audits Johnson & Johnson?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many shares of Johnson & Johnson are outstanding?
- 2.41 billion shares as of October 15, 2026, from its 10-Q filed October 21, 2026.
- What is Johnson & Johnson's public float?
- $367B as of June 29, 2025, as reported on the cover of its 10-K filed February 11, 2026.
- How many business segments does Johnson & Johnson report?
- 2 reportable segments for the period ending September 27, 2026, from its 10-Q filed October 21, 2026.
- When is Johnson & Johnson's annual shareholder meeting?
- March 11, 2026, per its proxy statement (DEF 14A) filed March 11, 2026.
- Have Johnson & Johnson insiders traded stock recently?
- Since July 17, 2025, officers and directors reported 20 open-market sales worth about $194M and 1 purchase worth about $258K on Forms 4 and 5. The most recent: Timothy Schmid (EVP, WW Chair, MedTech) sold 33,597 shares on September 2, 2026.